Ertugliflozin
CAS 1210344-57-2 3 FDA-DMF suppliersSmall Molecule
Overview
Ertugliflozin is a medication used for the treatment of type 2 diabetes. It acts as an SGLT2 inhibitor, reducing blood sugar levels by preventing glucose reabsorption in the kidneys.
Patent & exclusivity (US)
Per the FDA Orange Book (2 approved US products), the latest listed US patent on Ertugliflozin expires 19 Dec 2031. Generic API sourcing typically opens up once these lapse.
Therapeutic areas
Diabetes
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.